Eltrombopag Does NOT Cause Intracranial Hypertension
Based on FDA labeling and available clinical evidence, eltrombopag is not associated with causing intracranial hypertension. In fact, the opposite scenario has been documented—eltrombopag has been used to treat thrombocytopenia that resulted in intracranial hemorrhage 1, 2.
Key Evidence from FDA Drug Labeling
The FDA-approved labeling for eltrombopag lists the following clinically significant adverse reactions 1:
- Hepatotoxicity (including hepatic decompensation in hepatitis C patients)
- Thrombotic/thromboembolic complications (particularly portal vein thrombosis in chronic liver disease patients)
- Cataracts (developed or worsened in 7-11% of patients)
- Increased risk of progression of myelodysplastic syndromes to acute myeloid leukemia
Intracranial hypertension is notably absent from this list of warnings and adverse reactions.
Clinical Context: Eltrombopag Used to Prevent Intracranial Hemorrhage
The medical literature actually demonstrates eltrombopag being used therapeutically in situations where intracranial bleeding is a concern:
- A 2023 case report describes a patient with TKI-associated thrombocytopenia who developed intracranial hemorrhage and was successfully treated with eltrombopag to maintain platelet counts and prevent further bleeding 2
- Another 2026 case report documents refractory SLE-associated thrombocytopenia with risk of life-threatening complications including intracranial hemorrhage, where thrombopoietin receptor agonists were used as treatment 3
Important Caveats
While eltrombopag does not cause intracranial hypertension, clinicians should remain vigilant for its actual documented risks:
- Thrombotic complications: Portal vein thrombosis occurred in patients with chronic liver disease, particularly when platelet counts exceeded 200 × 10⁹/L 1
- Hepatotoxicity: Monitor liver function tests regularly
- Cataracts: Perform baseline and periodic ocular examinations 1
The confusion may arise because the evidence references intracranial hypertension guidelines 4 and traumatic intracranial hypertension management 5, but these are unrelated to eltrombopag's adverse effect profile.